Epidemiology of prostate cancer

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 5, 1997, Pages 273-287

  Haas, Gabriel P ^a   Sakr, Wael A ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAVY METAL; TESTOSTERONE;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CIGARETTE SMOKING; FAMILY HISTORY; FAT INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE DIFFERENCE; RISK FACTOR; SEXUAL BEHAVIOR; SOCIOECONOMICS; TESTOSTERONE BLOOD LEVEL; VASECTOMY;

EID: 0030772173     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.5.273     Document Type: Article

References (112)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Ries LAG, Kosary CL, Hankey BF, et al (eds): SEER Cancer Statistics Review, 1973-1994 (NIH Pub. No 97-2789). Bethesda. MD. National Cancer Institut, 1997.
3. Wingo PA, Landis S, Ries LAH: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997;47:239-242.
4. Potosky AL, Miller BA, Albertsen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
5. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testign. JAMA 1995;274:1445-1449.
6. Mettlin CJ, Murphy GP, Ho R, et al: The National Cancer Data Base report on longitudingal observations on prostate cancer. Cancer 1996;77:2162-2166.
7. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6.630 man. J Urol 1995;151:1283-1290.
8. Stephenson RA, Smart CR, Mineau GP, et al: The fall in incidence of prostate carcinoma: On the down side of a prostate-specific antigen induced peak in incidence: Data from the Utah Cancer Registry. Cancer 1996;77:1342-1348.
9. Shimizu H, Ross RK, Bernstein L, et al: Cancers of the prostate and brest among Japanese and white immigrants in Los angeles County. Br J Cancer 1991;63:963-966.
10. Parkin DM, Muir CS, Whelan SL, et al: Cancer Incidence in Five Continents, Vol VI (IARC Pub. No 120). Lyon, France, International Agency for Research on Cancer. 1992.
11. Tsugan S, Gotlieb SL, Laurenti R, et al: Cancer mortality among Japanese resident of the city of Sao Paulo, Brazil. Int J Cancer 1990;45:436-439.
12. Whittemore AS, Kolonel LN, Wu AH, et al: Prostate cancer relation to diet, physical activity, and body size in blacks, whites, and Asian in the United States and Canada. J Natl Cancer Inst 1995;87:652-661.
13. Boring CC, Squires TS, Heath CW Jr: Cancer statistics for African Americans. CA Cancer J Clin 1992;42:7-17.
14. Baquet CR, Horm JW, Gibbs T, et al: Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991;83:551-557.
15. Haas GP, Montie J, Pontes JE: The state of prostate cancer screening in the United States. Eur Urol 1993;23:337-347.
16. Kehinde EO: The geography of prostate cancer and its treatment in Africa. Cancer Surv 1995;23:281-286.
17. Elem B, Patil PS: pattern of urologic malignancy in Zambia: A hospital-based histopathologic study. Br J Urol 1991;67:37-39.
18. Jackson MA, Ahluwalia BS, Herson J, et al: Characterization of prostatic carcinoma among blacks: A continuation report. Cancer Treat Reports 1977;61:167-172.
19. Akhtar SS, Abu Bakr MA, Dawi SA, et al: Cancer in Lybia: A retrospective analysis. Afr J Med Med Sci 1993;22:17-24.
20. Slabber CF: A new South Africa: A new health care strategy. S Afr Med J 1992;82:388-391.
21. Bassett MT, Levy LM, Chetsanga C, et al: Zimbabwe National Cancer Registry: Summary data 1986-1989. Cent Afr J Med 1992;38:91-94.
22. Yatani R, Shiraishi T, Nakakuki K, et al: Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1988;80:683-687.
23. Sakr WA, Haas GP, Cassin BF, et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young males, J Urol 1993;150:379-385.
24. Tulinis H, Engilsson V, Olafsdottir GH, et al: Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992;305:855-857.
25. Cannon L, Bishop DT, Skolnick M, et al: Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1982-1:47-69.
26. Spitz MR, Currier RD, Fueger JJ, et al: Familial patterns of prostae cancer: a case-control analysis. J Urol 1991;1305-1307.
27. Gronberg H, Damber L, Damber JE: Studies of genetis factors in prostate cancer in a twin population. J Urol 1994;152:1484-1489.
28. Carter BS, Bova GS, Beaty TH, et al: Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993;150:797-802.
29. Morton RA Jr: Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994;44:637-647.
30. Pienta KJ, Demers R, Hoff M, et al: Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tricountry area: 1973to 1987. Urology 1995;45:93-102.
31. Powell IJ, Schwartz K, Hussain M: Removal of the financial barrier to health care: Does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans affairs sytem. Urology 1995;46:825-830.
32. Polednak AP: Cancer mortality in a higher-income black population in New York State: Comparison with rates in the United States as a whole. Cancer 1990;66:1654-1660.
33. Moul JW, Douglas TH, McCarthy WF, et al: Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access heath care setting. J Urol 1996;155:1667-1673.
34. Fowler JE Jr, Terrell F: Survival in blacks and whiles after treatment for localized prostate cancer. J Urol 1996;156:133-136.
35. Smith DS, Bullock AD, Catalona, WJ, et al. Racial differences in a prostate cancer screening study. J Urol 1996;156:1366-1369.
36. Schapira MM, McAuliffe TL, Nattinger AB Treatment of localized prostate cancer in African-American compared with Caucasian men: Less use of aggressive therapy for comparable disease. Medical Care 1995;33:1079-1088.
37. Hakky SI, Chisholm GD, Skeet RG: Social class and carcinoma of the prostate. Br J Urol 1979;51:393-396.
38. Greenwald P, Damon A, Kirrnss V, et al: Physical and demographic features of men before developing cancer of the prostate. J Natl Cancer Inst 1974;53:341-346.
39. Mahoney MC, Michalek AM: A meta-analysis of cancer incidence in United States and Canadian native populations. Int J Epidemiol 1991;20:323-327.
40. Miller BA, Kolonel LN, Bernstein L, et al (eds): Racial/Ethnic Patterns of Cancer in the United States 1988-1992 (NIH Pub. No. 96-4104). Washington, DC, US Department of Health and Human Services. National Institute of Health, 1996.
41. Liff JM. Chow WH Greenberg RS: Rural-urban differences in stage at diagnosis: Possible relationship to cancer screening. Cancer 1991;67:1454-1459.
42. Le Marchand L, Kolonel LN, Yoshizawa CN: Lifetime occupational physical activity and prostate cancer risk. Am J Epidemiol 1991;133:103-111.
43. Van der Gulden JW, Kolk JJ, Verbeek AL: Prostate cancer and work environment. J Occup Med 1992;34:402-409.
44. Matzkin H, Soloway MS: Cigarette smoking: A review of possible associations with benign prostat-ic hyperplasia and prostate cancer. Prostate 1993;22:277-290.
45. Feustel A, Wennrich R: Zinc and cadmium plasma and erythrocyte levels in prostatic carcinoma, BPH, urological malignancies, and inflammations. Prostate 1986;8:75-79.
46. Kolonel LN, Yoshizawa CN, Hankin JH: Diet and prostatic cancer: A case-control study in Hawaii. Am J Epidemiol 1988;127:999-1012.
47. Elghany NA, Schumacher MC, Slattery ML, et al: Occupation, cadmium exposure, and prostate cancer. Epidemiology 1990;1:107-115.
48. Checkoway H, DiFerdinando G, Hulka BS, et al: Medical, life-style, and occupational risk factors lot prostate-cancer. Prostate 1987;10:79-88.
49. Ross RK, Deapan DM, Casagrande JT, et al: A cohort sludy of mortality from cancer of the prostate in Catholic priests. Br J Cancer 1981;43:233-235.
50. Oishi K, Okada K, Yoshida O, et al: A case-control study of prostatic cancer in Kyoto, Japan: Sexual risk factors. Prostate 1990;17:269-279.
51. Giovannucci E, Ascherio A, Rimm EB, et al: A prospective-cohort sludy of vasectomy and prostate cancer in US men. JAMA 1993;269:873-877.
52. Giovannucci E, Tosteson TD, Spaizer FE, et al: A retrospectivc cohort study of vasectomy and prostate cancer in US men. JAMA 1993;269:878-882.
53. Mettlin C, Natarajan N, Huben R: Vasectomy and prostate cancer risk. Am J Epidemiol 1990;132:1056-1061.
54. Sidney S: Vascetomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol 1987;138:795-797.
55. DerSimonian R, Clemens J, Spirtas R, et al: Vasectomy and prostate cancer risk: Methodological review of the evidence J Clin Epidemiol 1993;46:163-172.
56. Ross RK, Paganini-Hiil A, Henderson BE: The etiology of prostate cancer: What does the epidemiology suggest? Prostate 1983;4:333-344.
57. Johnsonbaugh RE, O'Connell K, Engel M, et al: Plasma testosterone, luteinizing hormone, and follicle-stimulating hormone after vasectomy. Fertil Steril 1975;26:329-330.
58. De la Torre B, Hedman M, Jensen F, et al: Lack of an effect of vasectomy on peripheral gonadotrophin and steroid levels. Int J Androl 1983;6:125-134.
59. Alexander NJ, Free MJ, Paulsen CA, et al A comparison of blood chemistry, reproductive hormones, and the development of antisperm antibodies after vasectomy in men. J Androl 1980;1:40-50.
60. Anderson DJ, Alexander NJ, Fulgham DL, et al: Immunity to tumor-associated antigens in vasectomized men. J Natl Cancer Inst 1982;69:551-555.
61. Grignon D, Sakr W: Benign prostatic hyperplasia: Is it a premalignant lesion? In Vivo 1994;8:415-418.
62. Berry SJ, Coffey DS, Walsh PC, et al: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
63. Armenian HK, Lilienfeld AM, Diamond EL, et al: Relation between benign prostatic hyperplasia and canecr of the prostate: A prospective and retrospective study. Lancet 1974;53:115-117.
64. Greenwald P, Kirmss V. Polan AK, et al: Cancer of the prostate among men with benign prostatic hyperplasia J Natl Cancer Inst 1974;53;335-340.
65. Bostwick DG, Cooner WH, Denis L, et al: The association of benign prostatic hyperplasia and cancer of the prostate, Cancer 1992;70(Suppl 1):291-301.
66. Ghanadian R, Puah CM, O'Donoguhe EP: Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 1979;39:696-699.
67. Jackson MA, Kovi J, Heshmat MY, et al: Factors involved in the high incidence of prostatic cancer among American blacks. Prog Clin Biol Res 1981;53:111-132.
68. Meikle AW, Stanish WM: Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 1982;54:1104-1108.
69. Habib FK: Evaluation of androgen metabolism studies in human prostate cancer: Correlation with zinc levels, Prev Med 1980;9:650-656.
70. Geller J, Albert J, Loza D, et al: DHT concentrations in human prostate cancer tissue, J Clin Endocrinol Metab 1978;46:440-444.
71. Drafta D, Proca E, Zamfir V, et al: Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 1982;17:689-693.
72. Ross R, Bernstein L, Judd H, et al: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-48.
73. Ross R, Bernstein L, Lobo RA, et al: 5-alphareductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889.
74. Ellis L, Nyborg H: Racial/ethnic variations in male testosterone levels: A probable contributor to group differences in health. Steroids 1992;57:72-75?
75. Pienta KJ, Esper PS: Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
76. Armstrong B, Doll R: Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-631.
77. Le Marchand LL, Kolonel LN, Wilkens LR, et al: Animal fat consumption and prostate cancer: A prospective study in Hawaii. Epidemiology 1994;5:276-282.
78. Hirayama T: Epidemiology of prostate cancer with special reference to the role of diet. J Natl Cancer Inst Monogr 1979;53:149-155.
79. Van Poppel G, Goldbohm RA: Epidemiologic evidence for beta-carotene and cancer prevention. Am J Clin Nutr 1995;62(Suppl 6):1393S-1402S.
80. Adlercreutz H: Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ Health Perspect 1995;103(Suppl 7):103-112.
81. Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-2869.
82. Kadmon D, Thompson TC: Chemoprevention in prostate cancer, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams & Wilkins, 1996, pp 657-667.
83. Denton SE, Choy SH, Valk WL: Occult prostate carcinoma diagnosed by the step-section technique of surgical specimen. J Urol 1965;93:296-298.
84. Montie JE, Wood DP Jr, Pontes JE, et al: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989;63:381-385.
85. Kabalin JN, McNeal JE, Price HM, et al: Unsuspected adenocarcinorna of the prostate in patients undergoing cystoprostatectomy for other causes: Incidence, histology and morphometric observations. J Urol 1989;141:1091-1094.
86. Troncoso P, Babaian RJ, Ro JY, et al: Prostatic intraepitheilal neoplasia and invasive prostate adenocarcinoma in cystoprostatectomy specimens. Urology 1989;34(Supl 6):52-56.
87. Chun TY: Coincidence of bladder and prostate cancer. J Urol 1997;157:65-67.
88. Guileyardo JM, Johnson WD, Welsh RA, et al: Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980;65:311-316.
89. Sakr WA, Grignon DJ, Crissman JD, et al: High grade prostatic intraepithelial neoplasia (HGOIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo 1994;8:439-443.
90. Shiraishi T, Watanabe M, Matsuura H, et al: The frequency of latent prostate carcinoma in young males: The Japanese experience. In Vivo 1994;8:445-447.
91. Brawn PN, Speights VO, Contin JU, et al: Atypical hyperplasia in prostates of 20 to 40 year old men. J Clin Pathol 1989;42:383-386.
92. Gaudin PB, Epstein JI: Adenosis of the prostate: Histologic features in transurethral resection specimens. Am J Surg Pathol 1994;18:863-870.
93. Melhorn J: Problems of so-called atypical hyperplasia of the prostate. Zeitschrift fur Urologic und Nephrologie 1987;80:379-385.
94. Oian J. Bostwick DG: The extent and zonal location of prostatic intraepithelial neoplasta and atypical adenomatous hyperplasia: Relationship with carcinoma in radical prostatectomy specimens. Path Res Pract 1995;191:860-867.
95. Bostwick DG, Brawer MK: Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-794.
96. McNeal JE, Bostwick DG: Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
97. Bostwick DG: High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 1995;75:1823-1836.
98. McNeal JE: Morphogenesis of prostatic carcinoma. Cancer 1965;18:1659-1666.
99. Bostwick DG, Amin MB, Dundore P, et al: Architectural patterns of high-grade prostatic infraepithelial neoplasia. Hum Pathol 1993;24:298-310.
100. Sakr WA, Macoska JA, Benson P, et al: Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994;54:3273-3277.
101. Montironi R, Galluzzi CM, Diamanti L, et al: Prostatic intra-epithelial neoplasia: Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Path Res Pract 1993;189:542-548.
102. Nagle RB, Brawer MK, Kittelson J. et al: Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 1991;138:119-128.
103. Billis A: Age and race distribution of high grade prostatic intraepithelial neoplasia (HGPIN): An autopsy study in Brazil (South America). Mod Pathol 1996;9:71A.
104. Epstein JI, Cho KR, Quinn BD: Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 1990;65:2321-2327.
105. Quinn BD, Cho KR, Espstein JI: Relationship of severe dysplasia to stage B adenocarcinoma of the prostate. Cancer 1990;65:2328-2337.
106. Kovi J, Mostofi FK, Heshmat MY, et al: Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988;61:555-561.
107. Algaba F, Trias L, Lopez L, et al: Neuroendocrine cells in peripheral prostatic zone: Age, prostatic intraepithelial neoplasia and latent cancer-related changes, Eur Urol 1995;27:329-333.
108. McNeal JE, Villers A, Redwine EA, et al: Microcarcinoma in the prostate: Its association with duct-acinar dysplasia. Hum Pathol 1991;22:644-652.
109. Sakr WA, Grignon DJ, Haas GP, et al: Epidemiology of high grade prostatic intraeoithelial neoplasia. Pathol Res Pract 1995;191:838-841.
110. Bostwick DG, Srigley J, Grignon D, et al: Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993;24:819-832.
111. Gaudin PB, Epstein JI: Adenosis of the prostate: Histologic features in needle biopsy specimens. Am J Surg Pathol 1995;19:737-747.
112. Parker SL, Tong T, Bolden S, et al: Canter statistics 1997. CA Cancer J Clin 1997;47:5-27.